Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | glutamate receptor NMDA | 0.0088 | 0.377 | 0.245 |
Treponema pallidum | amino acid ABC transporter, periplasmic binding protein (hisJ) | 0.0048 | 0 | 0.5 |
Echinococcus multilocularis | nmda type glutamate receptor | 0.0098 | 0.4666 | 0.3536 |
Chlamydia trachomatis | glutamine binding protein | 0.0048 | 0 | 0.5 |
Echinococcus granulosus | nmda type glutamate receptor | 0.0098 | 0.4666 | 0.1439 |
Mycobacterium tuberculosis | Probable glutamine-binding lipoprotein GlnH (GLNBP) | 0.0048 | 0 | 0.5 |
Schistosoma mansoni | glutamate receptor NMDA | 0.0134 | 0.8068 | 0.5 |
Chlamydia trachomatis | arginine ABC transporter substrate-binding protein ArtJ | 0.0048 | 0 | 0.5 |
Treponema pallidum | amino acid ABC transporter, periplasmic binding protein | 0.0048 | 0 | 0.5 |
Mycobacterium ulcerans | glutamine-binding lipoprotein GlnH | 0.0048 | 0 | 0.5 |
Echinococcus multilocularis | nmda type glutamate receptor | 0.0155 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ID50 (functional) | = ng ml-1 | Antimalarial activity in vitro against Plasmodium falciparum and potency (ID50) was determined against Multidrug resistant Vietnam Smith strain | ChEMBL. | 6361258 |
ID50 (functional) | = ng ml-1 | Antimalarial activity in vitro against Plasmodium falciparum and potency (ID50) was determined against Chloroquine-susceptible pyrimethamine-resistant camp strain | ChEMBL. | 6361258 |
ID50 (functional) | = 0 ng ml-1 | Antimalarial activity in vitro against Plasmodium falciparum and potency (ID50) was determined against Multidrug resistant Vietnam Smith strain | ChEMBL. | 6361258 |
ID50 (functional) | = 0 ng ml-1 | Antimalarial activity in vitro against Plasmodium falciparum and potency (ID50) was determined against Chloroquine-susceptible pyrimethamine-resistant camp strain | ChEMBL. | 6361258 |
increase in mean survival time (functional) | day | In vivo Antimalarial activity against Plasmodium berghii in the mouse at 640 mg/kg dosage; T= Toxicity | ChEMBL. | 6361258 |
increase in mean survival time (functional) | day | In vivo Antimalarial activity against Plasmodium berghii in the mouse at 80 mg/kg dosage; C=cure | ChEMBL. | 6361258 |
increase in mean survival time (functional) | day | In vivo Antimalarial activity against Plasmodium berghii in the mouse at 160 mg/kg dosage; C=cure | ChEMBL. | 6361258 |
increase in mean survival time (functional) | day | In vivo Antimalarial activity against Plasmodium berghii in the mouse at 320 mg/kg dosage; T= Toxicity | ChEMBL. | 6361258 |
increase in mean survival time (functional) | C 0 day | In vivo Antimalarial activity against Plasmodium berghii in the mouse at 80 mg/kg dosage; C=cure | ChEMBL. | 6361258 |
increase in mean survival time (functional) | C 0 day | In vivo Antimalarial activity against Plasmodium berghii in the mouse at 160 mg/kg dosage; C=cure | ChEMBL. | 6361258 |
increase in mean survival time (functional) | T 0 day | In vivo Antimalarial activity against Plasmodium berghii in the mouse at 320 mg/kg dosage; T= Toxicity | ChEMBL. | 6361258 |
increase in mean survival time (functional) | T 0 day | In vivo Antimalarial activity against Plasmodium berghii in the mouse at 640 mg/kg dosage; T= Toxicity | ChEMBL. | 6361258 |
increase in mean survival time (functional) | = 4.7 day | Increase in mean survival time in Plasmodium berghii inoculated mice following 40 mg/kg administration. | ChEMBL. | 6361258 |
increase in mean survival time (functional) | = 4.7 day | Increase in mean survival time in Plasmodium berghii inoculated mice following 40 mg/kg administration. | ChEMBL. | 6361258 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.